TGFB1 and Marfan syndrome: Specifically, TGF-β signaling is activated in degenerative valves with ECM abnormalities and may be a potential therapeutic target, as TGF-β antagonists such as the angiotensin II type 1 receptor blocker, losartan, could prevent abnormal aortic root growth in a mouse model of Marfan syndrome (142).